《新股消息》传腾盛博药最快明年首季赴港上市 筹2亿至4亿美元
据《彭博》引述消息人士报道,内地生物科技公司腾盛博药正考虑最快明年第一季在香港进行IPO,目前公司正与投行研究上市可能,或筹资2亿至4亿美元。
消息人士指,上市计划仍处於初步阶段,规模和时间等细节仍可能有变。另外,腾盛亦在寻求上市前融资,向私募投资者集资约1亿美元。
据腾盛博药网站介绍,其研究范围包括乙型肝炎、爱滋病及新型冠状病毒及中枢神经系统疾病等,有两乙型肝炎项目在中国处临床2期阶段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.